Metabolic dysfunction-associated steatohepatitis (MASH)

The prevalence of MASH (Formerly known as NASH) is rising due to its association to diabetes mellitus, obesity hypertension and the metabolic syndrome. MASH has been neglected in clinical practice due to the lack of adequate diagnostic tools and effective treatment options other than lifestyle intervention programs. International guidelines have published comprehensive patient care pathways to help clinicians to identify patients at risk, providing guidance for diagnosis, follow up and treatment.

MASH clinical trials have notoriously high screening failure rates. Our clinical research experience and proprietary site networks enable us to implement innovative study design and execution tactics that fine-tune recruitment procedures, accelerate study startup, and shorten project timelines.

Meet our leaders for MASH clinical trials

Our scientific leader for MASH is Prof. dr. Manuel Castro Cabezas, a Julius Clinical scientific officer and senior consultant for internal medicine, endocrinology, and vascular medicine at the Franciscus Gasthuis Rotterdam. He has also been at the forefront of creating the MASH Think Tank, a group of leading MASH (NASH) experts who meet regularly to refine best practices.

Meet our leaders for MASH clinical trials

Julius Clinical is also proud to work with Prof. dr. Christophe Moreno, professor in gastroenterology and hepatology, clinical director of the liver unit at CUB Hôpital Erasme, Brussels, Belgium, and consultant to the MASH Clinical team.

Our proprietary network, MASH Clinical, is a global network of clinicians and investigators that includes endocrinologists, gastroenterologists, diabetologists, and general internists with connections to hospitals worldwide. They have vast experience as a group and are devoted to improving MASH (NASH) trials.

Read more

The leading experts of the MASH Think Tank meet on a regular basis to discuss the current state of the field and innovative approaches for MASH (formerly known as NASH) studies. Under Dr. Castro Cabezas’ leadership, they work to increase understanding of MASH, create expert centres for MASH clinical trials, and help provide better patient recruitment and retention rates for MASH Sponsors.

Prof. Manuel Castro Cabezas​, MD.

Chair and Scientific Officer at Julius Clinical

Prof. Dr. Christophe Moreno, MD.

Scientific board member

Prof. Dr. Diederick E. Grobbee, MD.

Board member and CSO at Julius Clinical

Prof. Maarten E. Tushuizen

Leidsch Universitair Medisch Centrum

Prof. Sven Francque

Antwerp University Hospital

Prof. Onno Holleboom

Amsterdam UMC

Prof. Jörn Schattenberg

University Medical Center Mainz

Prof. Helena Cortez-Pinto

Prof. Lawrence Serfaty

Hôpital Hautepierre Hôpitaux Universitaires Strasbourg

Prof. Manuel Romero Gomez

University of Seville

Prof. Marja Ritta Taskinen

Helsinki University Central Hospital

To help in the early identification of MASH patients and to improve collaboration in the screening strategy between GPs and clinicians, Julius Clinical initiated the Global Research Initiative for Patients screening on MASH (GRIPonMASH) research project. This is a multinational program in which at-risk patients are screened for MASLD and MASH (formerly known as NAFLD and NASH). Through GRIPonMASH awareness among health care professionals will increase resulting in a more efficient screening strategy for this rapidly growing clinical problem. In addition, GRIPonMASH will identify novel biomarkers facilitating early diagnosis. Julius Clinical and UMC Utrecht received an IHI grant (grant agreement ID. 101132946) for the GRIPonMASH project as from December the 1st 2023.

We are dedicated to providing fast, high-quality patient recruitment and retention rates for MASH clinical trials, Our team has years of experience and will provide a tailor-made solution that suits your trial’s exact needs.

Our expert MASH team

Julius Clinical has an expert team that can conduct streamlined global MASH (NASH) clinical trials. This in-house team brings insightful solutions to the biggest challenges, including scarcity of qualified sites and adequate access to patients.

Rick grobbee
Vivian de jong
Marcel bootsma
Marco alings
Elizabeth liano callahan

Related news & webinars

  • News
  • Cardio-Metabolic and Renal Diseases, MASH (NASH)

Metabolic dysfunction associated steatotic liver disease and the heart

Commentary by Dr. Marco Alings, MD PhD, Amphia Ziekenhuis, Breda; WCN, Utrecht; Scientific Officer at Julius ClinicalThe estimated prevalence of Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) in the adult population is 31% ...

By: Michelle Heuvelmans

MASH (NASH) resources

Explore our MASH capabilities, case studies, and other resources.


"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Request for proposal

"*" indicates required fields

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
This field is for validation purposes and should be left unchanged.


Twitter Facebook LinkedIn